Loading...

Nymox Pharmaceutical

DB:NYM
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NYM
DB
$131M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Nymox Pharmaceutical has significant price volatility in the past 3 months.
NYM Share Price and Events
7 Day Returns
3.5%
DB:NYM
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-50.9%
DB:NYM
-7.4%
DE Biotechs
-5.6%
DE Market
NYM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nymox Pharmaceutical (NYM) 3.5% -16.9% -12.1% -50.9% -13.5% -54.4%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • NYM underperformed the Biotechs industry which returned -7.4% over the past year.
  • NYM underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
NYM
Industry
5yr Volatility vs Market

Value

 Is Nymox Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Nymox Pharmaceutical. This is due to cash flow or dividend data being unavailable. The share price is €1.678.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nymox Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nymox Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NYM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.18
NasdaqCM:NYMX Share Price ** NasdaqCM (2019-04-24) in USD $1.93
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nymox Pharmaceutical.

DB:NYM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NYMX Share Price ÷ EPS (both in USD)

= 1.93 ÷ -0.18

-11.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nymox Pharmaceutical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Nymox Pharmaceutical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Nymox Pharmaceutical's expected growth come at a high price?
Raw Data
DB:NYM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Nymox Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Nymox Pharmaceutical's assets?
Raw Data
DB:NYM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.11
NasdaqCM:NYMX Share Price * NasdaqCM (2019-04-24) in USD $1.93
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:NYM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NYMX Share Price ÷ Book Value per Share (both in USD)

= 1.93 ÷ 0.11

17.83x

* Primary Listing of Nymox Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nymox Pharmaceutical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Nymox Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Nymox Pharmaceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Nymox Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nymox Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare Nymox Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Nymox Pharmaceutical's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Nymox Pharmaceutical's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:NYM Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NYM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NYM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -8 -11
2018-09-30 0 -7 -11
2018-06-30 0 -7 -13
2018-03-31 0 -7 -13
2017-12-31 0 -6 -13
2017-09-30 0 -6 -13
2017-06-30 0 -5 -11
2017-03-31 0 -4 -13
2016-12-31 0 -5 -13
2016-09-30 0 -4 -14
2016-06-30 0 -5 -21
2016-03-31 0 -5 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Nymox Pharmaceutical is high growth as no earnings estimate data is available.
  • Unable to determine if Nymox Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NYM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Nymox Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NYM Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.18
2018-09-30 -0.19
2018-06-30 -0.23
2018-03-31 -0.24
2017-12-31 -0.26
2017-09-30 -0.25
2017-06-30 -0.23
2017-03-31 -0.26
2016-12-31 -0.28
2016-09-30 -0.33
2016-06-30 -0.51
2016-03-31 -0.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Nymox Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Nymox Pharmaceutical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Nymox Pharmaceutical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Nymox Pharmaceutical's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Nymox Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nymox Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Nymox Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nymox Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nymox Pharmaceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Nymox Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Nymox Pharmaceutical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Nymox Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nymox Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NYM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.30 -10.59 4.13 6.68
2018-09-30 0.39 -11.20 4.01 7.42
2018-06-30 0.38 -12.99 5.05 8.12
2018-03-31 0.30 -13.28 5.11 8.16
2017-12-31 0.22 -13.43 5.44 7.87
2017-09-30 0.16 -12.94 5.68 7.05
2017-06-30 0.18 -11.48 4.37 6.85
2017-03-31 0.32 -12.60 5.74 6.78
2016-12-31 0.28 -13.11 6.18 6.80
2016-09-30 0.32 -14.39 6.68 7.55
2016-06-30 0.31 -21.27 10.35 10.81
2016-03-31 0.22 -22.80 12.82 9.79
2015-12-31 2.76 -17.89 11.61 8.65
2015-09-30 3.42 -14.27 10.64 6.96
2015-06-30 4.10 -4.95 6.39 2.60
2015-03-31 4.80 -0.42 2.06 3.09
2014-12-31 2.95 -4.59 3.00 4.50
2014-09-30 3.16 -5.42 2.77 5.38
2014-06-30 3.17 -5.75 2.84 5.62
2014-03-31 3.25 -6.41 2.88 6.28
2013-12-31 3.36 -4.91 2.04 5.72
2013-09-30 3.21 -6.41 1.99 7.29
2013-06-30 3.23 -6.63 1.90 7.62
2013-03-31 3.17 -6.87 2.03 7.73
2012-12-31 3.07 -7.63 2.13 8.28
2012-09-30 3.06 -6.47 2.21 7.01
2012-06-30 3.10 -6.84 2.46 7.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Nymox Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Nymox Pharmaceutical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Nymox Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Nymox Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nymox Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Nymox Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nymox Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nymox Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nymox Pharmaceutical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nymox Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Nymox Pharmaceutical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nymox Pharmaceutical Company Filings, last reported 3 months ago.

DB:NYM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7.00 0.00 7.95
2018-09-30 3.93 0.00 4.66
2018-06-30 3.55 0.00 5.04
2018-03-31 -1.04 0.00 0.85
2017-12-31 -1.25 0.00 0.85
2017-09-30 0.01 0.55 1.74
2017-06-30 -0.72 0.65 1.26
2017-03-31 -1.17 0.96 1.63
2016-12-31 -0.24 0.93 2.02
2016-09-30 -1.02 0.90 1.57
2016-06-30 -1.80 0.87 0.16
2016-03-31 -1.10 0.84 0.83
2015-12-31 -2.35 0.81 0.37
2015-09-30 -2.71 0.79 0.16
2015-06-30 -1.52 0.77 0.87
2015-03-31 -1.99 0.74 0.38
2014-12-31 -3.78 0.72 0.63
2014-09-30 -4.19 0.00 0.20
2014-06-30 -5.36 0.00 0.08
2014-03-31 -5.85 0.00 0.25
2013-12-31 -5.66 0.00 0.30
2013-09-30 -5.50 0.00 0.65
2013-06-30 -6.46 0.00 0.74
2013-03-31 -6.12 0.00 1.38
2012-12-31 -7.04 0.00 1.03
2012-09-30 -7.34 0.00 1.56
2012-06-30 -7.28 0.00 2.19
  • Nymox Pharmaceutical has no debt.
  • Nymox Pharmaceutical had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Nymox Pharmaceutical has less than a year of cash runway based on current free cash flow.
  • Nymox Pharmaceutical has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.5% each year.
X
Financial health checks
We assess Nymox Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nymox Pharmaceutical has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Nymox Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Nymox Pharmaceutical dividends.
If you bought €2,000 of Nymox Pharmaceutical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Nymox Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Nymox Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NYM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Nymox Pharmaceutical has not reported any payouts.
  • Unable to verify if Nymox Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Nymox Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Nymox Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Nymox Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nymox Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nymox Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Nymox Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Averback
COMPENSATION $3,499,991
AGE 67
CEO Bio

Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceutical Corporation and has been its Chairman since June 2001. He has been a Director of Nymox Pharmaceutical Corporation since September 20, 1995. He served as the President of Nymox's predecessor, DMS Pharmaceuticals Inc. He has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer's disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. He received his M.D. (Medical Research Council Postdoctoral Fellow) in 1975 and taught pathology at universities, including Cambridge University, England from 1977 to 1980, during which time he initiated his research on Alzheimer's disease. He has Practiced Medicine in Numerous Canadian institutions as well as in private practice. Dr. Averback holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology and was on the Faculty of Medicine at McGill University.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year.
  • Paul's remuneration is higher than average for companies of similar size in Germany.
Management Team

Paul Averback

TITLE
Founder
COMPENSATION
$3M
AGE
67

Erik Danielsen

TITLE
Chief Financial Officer
COMPENSATION
$443K
AGE
55
TENURE
3.8 yrs

Randall Lanham

TITLE
General Counsel
COMPENSATION
$537K
AGE
54
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Nymox Pharmaceutical board of directors in years:

12.8
Average Tenure
61
Average Age
  • The average tenure for the Nymox Pharmaceutical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Paul Averback

TITLE
Founder
COMPENSATION
$3M
AGE
67
TENURE
17.8 yrs

Randall Lanham

TITLE
General Counsel
COMPENSATION
$537K
AGE
54
TENURE
12.8 yrs

James Robinson

TITLE
Director
COMPENSATION
$5K
AGE
83
TENURE
4.3 yrs

Rich Cutler

TITLE
Lead Independent Director
COMPENSATION
$5K
AGE
60

David Morse

TITLE
Independent Director
COMPENSATION
$5K
AGE
61
TENURE
12.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Jan 19 Buy Erik Danielsen Individual 19. Dec 18 21. Dec 18 11,000 €1.35 €13,840
14. Dec 18 Buy James Robinson Individual 13. Dec 18 13. Dec 18 5,237 €1.51 €7,933
13. Dec 18 Buy James Robinson Individual 12. Dec 18 12. Dec 18 6,000 €1.51 €9,054
12. Dec 18 Buy James Robinson Individual 11. Dec 18 11. Dec 18 5,000 €1.48 €7,382
11. Dec 18 Buy James Robinson Individual 10. Dec 18 10. Dec 18 7,500 €1.42 €10,673
10. Dec 18 Buy James Robinson Individual 07. Dec 18 07. Dec 18 7,000 €1.48 €10,372
07. Dec 18 Buy James Robinson Individual 06. Dec 18 06. Dec 18 1,400 €1.53 €2,142
06. Dec 18 Buy James Robinson Individual 04. Dec 18 04. Dec 18 7,500 €1.51 €11,360
03. Dec 18 Buy James Robinson Individual 30. Nov 18 30. Nov 18 5,000 €1.63 €8,125
30. Nov 18 Buy James Robinson Individual 29. Nov 18 29. Nov 18 7,000 €1.59 €11,126
28. Nov 18 Buy James Robinson Individual 27. Nov 18 27. Nov 18 8,000 €1.51 €12,113
21. Nov 18 Buy James Robinson Individual 16. Nov 18 20. Nov 18 21,000 €1.69 €33,311
15. Nov 18 Buy James Robinson Individual 13. Nov 18 13. Nov 18 7,000 €1.77 €12,400
13. Nov 18 Buy James Robinson Individual 09. Nov 18 09. Nov 18 13,000 €1.88 €24,007
09. Nov 18 Buy James Robinson Individual 07. Nov 18 07. Nov 18 363 €1.78 €645
06. Nov 18 Buy Randall Lanham Individual 28. Oct 18 28. Oct 18 2,900 €1.51 €4,382
06. Nov 18 Sell Paul Averback Individual 26. Oct 18 29. Oct 18 -1,787,600 €2.20 €-3,860,129
06. Nov 18 Buy James Robinson Individual 02. Nov 18 02. Nov 18 7,000 €1.74 €12,158
02. Nov 18 Buy James Robinson Individual 01. Nov 18 01. Nov 18 6,000 €1.67 €10,006
01. Nov 18 Buy James Robinson Individual 30. Oct 18 31. Oct 18 18,000 €1.59 €28,417
26. Oct 18 Buy James Robinson Individual 25. Oct 18 25. Oct 18 10,000 €1.43 €14,267
25. Oct 18 Buy James Robinson Individual 22. Oct 18 22. Oct 18 8,000 €1.45 €11,634
X
Management checks
We assess Nymox Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nymox Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Details
Name: Nymox Pharmaceutical Corporation
NYM
Exchange: DB
Founded: 1989
$116,704,658
67,676,256
Website: http://www.nymox.com
Address: Nymox Pharmaceutical Corporation
Bay & Deveaux Streets,
2nd Floor,
Nassau,
Bahamas
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NYMX Common Shares Nasdaq Capital Market US USD 26. Nov 1997
DB NYM Common Shares Deutsche Boerse AG DE EUR 26. Nov 1997
Number of employees
Current staff
Staff numbers
0
Nymox Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:57
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.